LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compact Immunoassay and Clinical Chemistry Analyzer Helps Low- to Mid-Volume Labs Tackle Challenges

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The Atellica CI Analyzer offers the highest throughput in the smallest footprint (Photo courtesy of Siemens)
Image: The Atellica CI Analyzer offers the highest throughput in the smallest footprint (Photo courtesy of Siemens)

Clinical laboratories face crucial operational challenges that hinder productivity, such as an increased number of patient samples, staff shortages, and additional documentation requirements. Now, a new immunoassay and clinical chemistry testing system is designed to address these issues related to labor shortages, while also promoting revenue growth and enhancing agility beyond standardization and clinical equivalence. Workflow improvements offered by this system can aid laboratories in achieving more predictable turnaround times, reducing reporting duties, and allowing staff to concentrate on essential lab operations.

Every lab, irrespective of its size, grapples with significant challenges arising from labor shortages. These range from ensuring reliable test results to facilitating predictable care, protecting staff, securing data, and achieving environmental objectives. The Atellica CI Analyzer from Siemens Healthineers (Erlangen, Germany) enables both standalone labs and satellite labs of wider health networks to access the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution, but now in a compact 1.9 square meters footprint ideal for smaller laboratories. Labs with low to medium testing volumes will appreciate the competitive edge offered by the Atellica CI Analyzer, including improved turnaround time predictability, advanced reporting functionality, and robust safety and security measures.

Designed with standout capabilities, the Atellica CI Analyzer maximizes downtime usage and bolsters lab efficiency and profitability. Features like random access sampling, micro-volume aspiration, and automatic scheduling for maintenance and quality control enable labs to deliver more predictable sample turnaround times. The independent operation of chemistry and immunoassay engines ensures that throughput isn't compromised if one of the two needs to be halted. In addition to producing patient results, labs also need to meet reporting requirements, address cybersecurity, and achieve staff satisfaction goals. The Atellica CI Analyzer comes with the Atellica Laboratory Evaluation Suite to provide inspection-ready reports, helping labs meet accreditation guidelines without requiring additional software and allowing laboratory staff to redirect their efforts toward other important lab operations. Increased security measures are also available, including user authentication, role-based authorizations, and audit trails. With a planned menu of over 200 assays spanning 20 disease states, each lab in a health network can select the best tests for its patient population, fulfilling clinical needs that might otherwise be unmet. More than 50 key assays can produce results in less than 14 minutes.

"Workflow standardization and clinical equivalence are critical components of a successful laboratory operation within a health network. The Atellica CI Analyzer elevates laboratory operations to a new level of agility," said Sharon Bracken, head of Diagnostics for Siemens Healthineers. "Labs today need testing instrumentation and informatics that can easily keep pace with rapidly changing testing demands as they occur. This next-generation laboratory analyzer anticipates workflow bottlenecks, mitigates them proactively, and delivers insights based on data that help laboratory staff do their job more effectively and efficiently."

Related Links:
Siemens Healthineers 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.